



April 30, 2015

## **Esperion Therapeutics to Provide First Quarter 2015 Results**

### **Conference Call and Webcast on Thursday, May 7, 2015 at 4:30 p.m. Eastern Time**

ANN ARBOR, MI -- (Marketwired) -- 04/30/15 --

Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced it will host a conference call and webcast to report operational and financial results for the first quarter 2015. The webcast will take place on Thursday, May 7, 2015 at 4:30 p.m. Eastern Time.

The call can be accessed by dialing (877) 831-3840 (domestic) or (253) 237-1184 (international) five minutes prior to the start of the call and providing access code 92733088. A live, listen-only webcast of the conference call can be accessed on the investor relations section of the Esperion website at [www.esperion.com](http://www.esperion.com). A webcast replay of the call will be available approximately two hours after completion of the call and will be archived on the company's website for two weeks.

#### ***Esperion's Commitment to Cardiometabolic Disease***

Esperion is committed to improving the lives of patients with cardiometabolic diseases. The Esperion team leverages its understanding of, and experience with, key biological pathways to discover and develop innovative therapies for the treatment of patients with hypercholesterolemia who have uncontrolled cholesterol levels despite the use of currently available therapies. Esperion has assembled a portfolio of programs including one product candidate in late-stage clinical evaluation (ETC-1002) and two pre-clinical product candidates.

#### ***About Esperion Therapeutics***

Esperion Therapeutics, Inc. is an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, LDL-cholesterol-lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. ETC-1002 (bempedoic acid), Esperion's lead product candidate, is a first-in-class, orally available, once-daily small molecule designed to lower LDL-cholesterol levels and avoid the side effects associated with currently available LDL-cholesterol lowering therapies. ETC-1002 is being developed for patients with primary hyperlipidemia and mixed dyslipidemia. For more information, please visit [www.esperion.com](http://www.esperion.com) and follow us on Twitter at <https://twitter.com/EsperionInc>.

#### **Media Contact:**

Elliot Fox  
W2O Group  
212.257.6724  
[efox@w2ogroup.com](mailto:efox@w2ogroup.com)

#### **Investor Contact:**

Barbara Ryan  
Clermont Partners  
203.274.2825  
[bryan@esperion.com](mailto:bryan@esperion.com)

Source: Esperion Therapeutics, Inc.

News Provided by Acquire Media